10.86
3.43%
+0.36
Agenus Inc stock is currently priced at $10.86, with a 24-hour trading volume of 429.44K.
It has seen a +3.43% increased in the last 24 hours and a +101.11% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $10.52 pivot point. If it approaches the $10.98 resistance level, significant changes may occur.
Previous Close:
$10.50
Open:
$10.5
24h Volume:
429.44K
Market Cap:
$228.05M
Revenue:
$156.31M
Net Income/Loss:
$-245.76M
P/E Ratio:
-12.78
EPS:
-0.85
Net Cash Flow:
$-234.16M
1W Performance:
+3.53%
1M Performance:
+101.11%
6M Performance:
+1,474%
1Y Performance:
+638.78%
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4400
Address
3 Forbes Road, Lexington, MA
Agenus Inc Stock (AGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-06-23 | Initiated | Robert W. Baird | Outperform |
Feb-28-23 | Resumed | H.C. Wainwright | Buy |
Sep-28-22 | Initiated | SMBC Nikko | Outperform |
Dec-16-21 | Initiated | H.C. Wainwright | Buy |
Nov-19-19 | Resumed | B. Riley FBR | Buy |
Apr-22-19 | Initiated | B. Riley FBR | Buy |
Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-27-16 | Reiterated | Maxim Group | Buy |
Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
Dec-16-15 | Initiated | Jefferies | Buy |
Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
Jul-27-15 | Reiterated | MLV & Co | Buy |
Jun-11-15 | Initiated | Oppenheimer | Outperform |
Jan-12-15 | Reiterated | Maxim Group | Buy |
Jan-09-15 | Reiterated | MLV & Co | Buy |
Jan-09-15 | Reiterated | Maxim Group | Buy |
Dec-19-14 | Reiterated | Maxim Group | Buy |
May-08-14 | Reiterated | Maxim Group | Buy |
Mar-14-14 | Reiterated | MLV & Co | Buy |
Oct-08-13 | Reiterated | Maxim Group | Buy |
Jan-05-12 | Initiated | William Blair | Outperform |
Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus announces reverse stock split of common stock - MSN
MSN
Agenus sets FDA meeting for cancer therapy path - Investing.com Canada
Investing.com Canada
Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know - Yahoo Singapore News
Yahoo Singapore News
Agenus sets FDA meeting for cancer therapy path - Investing.com
Investing.com
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory ... - Business Wire
Business Wire
Therapeutic Vaccines Market Drivers, Size, Biggest Share, - openPR
openPR
Agenus Inc Stock (AGEN) Financials Data
Agenus Inc (AGEN) Revenue 2024
AGEN reported a revenue (TTM) of $156.31 million for the quarter ending December 31, 2023, a +59.46% rise year-over-year.
Agenus Inc (AGEN) Net Income 2024
AGEN net income (TTM) was -$245.76 million for the quarter ending December 31, 2023, a -11.67% decrease year-over-year.
Agenus Inc (AGEN) Cash Flow 2024
AGEN recorded a free cash flow (TTM) of -$234.16 million for the quarter ending December 31, 2023, a -2.50% decrease year-over-year.
Agenus Inc (AGEN) Earnings per Share 2024
AGEN earnings per share (TTM) was -$14.00 for the quarter ending December 31, 2023, a +11.39% growth year-over-year.
About Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Cap:
|
Volume (24h):